The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy
- PMID: 6815701
- DOI: 10.1007/BF00470594
The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy
Abstract
Chronic treatment with dopamine (DA) agonists has been reported in various paradigms to cause supersensitivity of DA receptors or, contradictorily, subsensitivity of DA receptors. The present study administered 15 mg/kg bromocriptine for 7 days and measured both striatal spiperone binding and apomorphine (AP)-induced stereotypy. A significant decrease in AP-induced stereotypies was observed after chronic bromocriptine treatment, but without a significant parallel decrease in striatal spiperone binding. These results probably do not represent a true agonist-induced subsensitivity, but possibly show that residual bromocriptine in vivo may antagonize AP-induced stereotypy. Since some reports have suggested that L-Dopa may specifically reverse the increases in DA receptor number induced by chronic haloperidol, we also studied the effect of 7 days of L-Dopa treatment after 6-week chronic haloperidol treatment of mice. While chronic haloperidol significantly increased striatal spiperone binding, subsequent L-Dopa treatment did not reverse this biochemical supersensitivity. It is concluded that agonist induction of subsensitivity in the DA system is difficult to reproduce and may depend on highly specific dosage conditions and treatment schedules.
Similar articles
-
Combined administration of direct dopamine receptor agonists and L-dopa does not interfere with utilization of exogenous L-dopa in rat corpus striatum.Prog Neuropsychopharmacol Biol Psychiatry. 1983;7(2-3):211-5. doi: 10.1016/0278-5846(83)90109-4. Prog Neuropsychopharmacol Biol Psychiatry. 1983. PMID: 6310691
-
Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.Clin Neuropharmacol. 1984;7(3):247-57. Clin Neuropharmacol. 1984. PMID: 6435870
-
Aging and the regulation of striatal dopaminergic mechanisms in mice.J Pharmacol Exp Ther. 1981 Dec;219(3):695-700. J Pharmacol Exp Ther. 1981. PMID: 7197719
-
Receptor changes during chronic dopaminergic stimulation.J Neural Transm Suppl. 1988;27:161-75. doi: 10.1007/978-3-7091-8954-2_14. J Neural Transm Suppl. 1988. PMID: 2900291 Review.
-
On the mechanism of the antiparkinsonian action of 1-DOPA and bromocriptine: a theoretical and experimental analysis of dopamine receptor sub- and supersensitivity.J Neural Transm Suppl. 1980;(16):69-81. doi: 10.1007/978-3-7091-8582-7_8. J Neural Transm Suppl. 1980. PMID: 7000979 Review.
Cited by
-
Lack of cross-sensitization between the locomotor-activating effects of bromocriptine and those of cocaine or heroin.Psychopharmacology (Berl). 1993;110(4):402-8. doi: 10.1007/BF02244645. Psychopharmacology (Berl). 1993. PMID: 7870909
-
The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats.Psychopharmacology (Berl). 1985;85(4):405-9. doi: 10.1007/BF00429654. Psychopharmacology (Berl). 1985. PMID: 3927334
-
L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.Psychopharmacology (Berl). 1987;91(2):254-6. doi: 10.1007/BF00217074. Psychopharmacology (Berl). 1987. PMID: 3107042
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources